Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IN10018 + Furmonertinib in Advanced EGFR+ NSCLC
NCT05994131Phase 2Recruiting
- Sponsor
- InxMed
- Start
- Jul 2023
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ifebemtinib in non-small cell lung cancer (NSCLC), sponsored by InxMed. Started Jul 2023; status: recruiting.
02
Drugs
ifebemtinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05994131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05994131.